urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

Tecentriq misses the mark in advanced ovarian cancer

Roche’s drug is approved in a range of cancer types, including urothelial carcinoma, triple-negative cancer and hepatocellular carcinoma.

Latest news

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... The initial results from the phase 1b/2 EV-103
Keytruda claims first place in bladder cancer race

covers patients with early-stage high grade cancer cells – carcinoma-in-situ (CIS) – with or without papillary tumours. ... Keytruda has already been approved for first- and second-line treatment of urothelial carcinoma, another form of bladder
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

In May 2017, Bavencio (avelumab) claimed approval as a second-line treatment in patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease progressed during or following platinum-containing chemotherapy. ... Our unique
J&J taps TARIS Biomedical for novel bladder cancer technology

Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) is also approved for first- and second-line treatment of urothelial carcinoma, the most common form of bladder cancer.
Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Keytruda has already been

More from news
Approximately 3 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Unlocking the potential of precision medicine in oncology

those living with urothelial carcinoma (UC), the most common type of bladder cancer.
Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

Medical Editor: Competitive

Healthcare Senior Account Manager: Competitive

Healthcare Lead Copywriter: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....